Led by Legend Capital, GS Biotech Completes Nearly CNY100 million Pre-A Round Financing
Retrieved on:
Friday, December 9, 2022
Giant, Synthetic biology, Recycling, Chemical physics, R, Hangzhou, Inc., HMF, Carbon, Chinese Academy of Sciences, Biomass, Health, Polymer, Negotiation, RMB, Information science, FDCA, USD, UNPRI, PGA, Research, Investment, Dalian Institute of Chemical Physics, Shenzhen Kaifa Technology Co., Ltd., AI, ESG, VC, Renewable energy, Fine chemical, Science
HONG KONG, Dec 9, 2022 - (ACN Newswire) - Recently, Zhongke Guosheng (Hangzhou) Technology Co., Ltd (hereinafter referred to as "GS Biotech") officially announced the completion of its nearly CNY100 million pre-A round financing, led by Legend Capital.
Key Points:
- HONG KONG, Dec 9, 2022 - (ACN Newswire) - Recently, Zhongke Guosheng (Hangzhou) Technology Co., Ltd (hereinafter referred to as "GS Biotech") officially announced the completion of its nearly CNY100 million pre-A round financing, led by Legend Capital.
- Founded in 2021 with the vision of "Biomass Change Lives", GS Biotech is a bio-based material and R&D company dedicated to building a bio-based material industry chain.
- GS Biotech has pioneered the HMF continuous production process globally and realized the large-scale and low-cost production of HMF.
- The core team of GS Biotech graduated from the Dalian Institute of Chemical Physics of the Chinese Academy of Sciences.